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Abstract
Amiodarone-induced thyroid dysfunction (AITD) is a common complication of amiodarone therapy and its prevalence varies 
according to iodine intake, subclinical thyroid disorders and the definition of AITD. There is no consensus about the frequency 
of screening for this condition. We evaluated 121 patients on chronic regular intake of amiodarone (mean intake = 248.5 ± 89 
mg; duration of treatment = 5.3 ± 3.9 years, range = 0.57-17 years) and with stable baseline cardiac condition. Those with no 
AITD were followed up for a median period of 3.2 years (range: 0.6-6.7) and the incidence rate of AITD, defined by clinical and 
laboratorial findings as proposed by international guidelines, was obtained (62.8 per 1000 patients/year). We applied the Cox 
proportional hazard model to adjust for potential confounding factors and used sensitivity analysis to identify the best screening 
time for follow-up. We detected thyroid dysfunction in 59 (48.7%) of the 121 patients, amiodarone-induced hypothyroidism in 
50 (41.3%) and hyperthyroidism in 9 (7.5%). Compared with patients without AITD, there was no difference regarding dosage 
or duration of therapy, heart rhythm disorder or baseline cardiac condition. During the follow-up of the 62 patients without AITD 
at baseline evaluation, 11 developed AITD (interquartile range, IR: 62.8 (95%CI: 31.3-112.3) cases per 1000 patients/year), 9 
of them with hypothyroidism - IR: 11.4 (95%CI: 1.38-41.2), and 2 hyperthyroidism - IR: 51.3 (95%CI: 23.4-97.5). Age, gender, 
dose, and duration of treatment were not significant after adjustment. During the first 6 months of follow-up the incidence rate 
for AITD was 39.3 (9.2-61.9) cases per 1000 patients/year. These data show that AITD is quite common, and support the need 
for screening at 6-month intervals, unless clinical follow-up dictates otherwise or further information regarding the prognosis of 
untreated subclinical AITD is available.
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Amiodarone is a diiodinated benzofuran derivative 
widely used for its antiarrhythmic properties (1). Recently, it 
has been included in the American Heart Association guide-
lines for cardiac arrest and emergency care (2). Although 
it has proved to be a very effective drug for the treatment 
of cardiac arrhythmias, its chronic use is associated with 
significant side effects. Among these, thyroid dysfunction is 
a common manifestation (3), even when a low daily dose 
regime of amiodarone is used. The exact prevalence and 
pathogenesis of amiodarone-induced thyrotoxicosis (AIT) 
or hypothyroidism (AIH) are unknown, but they are associ-
ated with several factors. First, there is a very important 
relationship with iodine intake, so that in regions where 
an inadequate low intake occurs, a greater prevalence 
of AIT and goiter will be detected, while in areas where a 
sufficient iodine intake is observed, a greater prevalence 
of AIH can be detected (4). Second, the criteria used to 
define AIT have to be taken into consideration, since com-
mon symptoms of thyroid dysfunction can be masked by 
the effects of amiodarone, so that thyroid dysfunction can 
only be diagnosed by active thyroid hormone evaluation 
(1). Third, the time when the hormone level is determined 
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is very important since fluctuation can occur, especially at 
the beginning of treatment (4). Fourth, AIT can be caused 
by direct (drug effect on the thyroid gland inducing a de-
structive thyroiditis) or indirect (exacerbating subclinical 
conditions such as pre-existing or “latent” thyroid disease 
by a multinodular goiter ou Graves’ disease) effects of the 
drug (1,4,5). It should be mentioned that in most of the 
previously published studies the differentiation between 
these mechanisms of AIT was not available. 
In view of these considerations, screening for thyroid 
function has been recommended in several guidelines (4,6-
8), but there is no consensus concerning the recommended 
frequency of this screening process. Intervals varying from 
3 months to more than 1 year have been recommended. 
Thus, the objective of the present study was to evaluate the 
incidence of thyroid dysfunction in cardiac patients using 
amiodarone on regular basis for more than one year, after 
excluding prevalent thyroid dysfunction. The results of this 
evaluation should be helpful for determining the most appro-
priate interval for amiodarone-induced thyroid dysfunction 
(AITD) screening during chronic use of amiodarone.
Material and Methods
Study population and exposure 
A total of 121 patients (43.8% males; 58.3 ± 13.2 
years old) using amiodarone for cardiac rhythm disorders 
were selected consecutively among patients who sought 
medical attention between 2000 and 2001 at the cardiology 
outpatient clinic of the University Hospital, Medical School 
of Ribeirão Preto, University of São Paulo, Ribeirão Preto, 
SP, Brazil. The patients had been using amiodarone on a 
daily basis for a median period of 30 months (interquartile 
range: 16-56), with an average dose of less than 250 mg/
day. They did not have any known thyroid disease before 
starting amiodarone and had clinically stable heart disease 
at the time when they were invited to participate in the 
study and their thyroid function hormones were evaluated. 
Demographic and clinical data regarding age, gender, amio-
darone dose, type of cardiac rhythm disorder, and baseline 
cardiovascular disease were collected for all patients.
The patients were submitted to clinical and laboratory 
evaluation by an endocrine disease specialist for charac-
terization of their thyroid function status. Patients who were 
found to have any thyroid dysfunction (50 patients with 
hypothyroidism and 9 patients with hyperthyroidism) were 
excluded from follow-up and referred to the endocrinol-
ogy outpatient clinic for follow-up and treated accordingly. 
Of the remaining 62 patients presenting normal thyroid 
function at baseline, 9 were excluded from analysis since 
amiodarone was discontinued based on clinical decision. 
The remaining 53 patients were followed for a mean of 3.2 
years (median 3.2; range 0.6-16.5) for thyroid dysfunction at 
6-month intervals. The protocol was approved by the Ethics 
Committee of Faculdade de Medicina de Ribeirão Preto, 
Universidade de São Paulo (HCRP No. 8557/2004), and 
written informed consent was obtained from each patient.
Thyroid function evaluation 
In addition to a complete medical history and physical 
examination emphasizing thyroid-related signs and symp-
toms, clinical evaluation included the determination of serum 
thyrotrophin (TSH), free thyroxine (FT4), free triiodothyrox-
ine (FT3), and thyroid auto-antibodies. TSH, FT4, and FT3 
were measured by a chemiluminescent method (Immulite 
2000, DPC Cirrus Inc., USA) with sensitivity of 0.02 µU/
mL, 0.15 ng/dL, and 1.0 pg/mL, respectively. The intra-
assay coefficient of variation (CV) was 3.8, 5.2 and 3.5%, 
and interassay CV was 3.5, 14, and 14.6%, respectively. 
Anti-peroxidase (anti-TPO) antibodies were measured by 
a chemiluminescent method (Immulite 2000, DPC Cirrus 
Inc.) with an intra-assay CV of 2.3% and an interassay CV 
of 10.5%. Reference values were 0.3-4.0 mU/L for TSH, 1.5-
4.1 pg/mL for FT3, and 0.7-1.7 ng/dL for FT4, and anti-TPO 
values above 35 U/L were considered to be positive.
Definition of thyroid dysfunction 
Hormone determinations and/or clinical evidence of 
thyroid dysfunction were used to identify patients present-
ing thyroid dysfunction. Patients with TSH lower than 0.1 
mU/L were considered to have hyperthyroidism, which was 
defined as subclinical if FT3 and FT4 were normal and 
clinical if FT3 and/or FT4 were high. Patients with TSH 
equal to or higher than 4.5 mU/L were considered to have 
hypothyroidism, which was defined as subclinical if FT3 
and FT4 were normal and clinical if FT3 and/or FT4 were 
low. The criterion used to diagnose hyperthyroidism was 
based on the guidelines of the American Thyroid Associa-
tion, suggesting that virtually all cases of hyperthyroidism 
encountered in clinical practice are accompanied by a 
serum TSH concentration lower than 0.1 mU/L and not by 
TSH just below the normal range (9).
Statistical analysis 
Demographic and clinical characteristics were compared 
using chi-square tests or non-parametric tests (Kruskal-
Wallis or Mann-Whitney) as applicable. Crude AITD inci-
dence rates and 95% confidence intervals (95%CI) were 
calculated using time-to-event methods. The proportion of 
individuals remaining free of incident AITD at any time during 
follow-up was calculated using the Kaplan-Meier method. 
For all survival analyses, the follow-up time was defined 
as the period from entry into the study to AITD diagnosis 
or up to the time an individual left the study. We used Cox 
proportional hazard models to adjust for age (years), gender, 
drug dose, and duration of treatment. We also performed a 
sensitivity analysis, limiting the follow-up to 6 months and 1 
year to evaluate the impact of time on the AITD incidence 
rate. All analyses were conducted using the Stata version 
9.2 software (10).
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Results
Of the 121 patients studied, 59 were diagnosed with 
AITD at the beginning of the study indicating a prevalence 
rate of 48.7%: 50 with AIH (41.3%) and 9 (7.5%) with AIT. 
Comparison of these 59 patients who presented thyroid 
disfunction at the beginning of the study with the 62 euthyroid 
patients can be found in Table 1. Even though the patients 
with AIT tended to be older than the AIH and euthyroid 
patients, no significant difference was found between 
groups. There was a greater prevalence of female gender 
among participants with AITD. Amiodarone dose, treatment 
duration and prevalence of cardiac rhythm disorder did not 
differ between groups. Of interest, Chagas’ cardiomyopathy 
was highly prevalent in our population using amiodarone 
(43.4%), but no demographic or clinical difference could be 
demonstrated when we compared Chagas’ disease patients 
to patients with other cardiomyopathies or presenting any 
other baseline cardiac disease. Anti-TPO levels were higher 
in the hypothyroid group.
Of the 50 patients diagnosed with AIH, only 16 (32%) 
had clinical signs and symptoms, while most AIT patients 
had overt clinical disease (77.7%). There was no difference 
in the demographic and clinical characteristics regarding 
patients with AIH when we compared those presenting clini-
cal manifestations with those who had subclinical disease 
(Table 2), except for TSH and FT4 levels. 
During the follow-up of patients who were euthyroid at 
baseline (62; 51.2%), 9 discontinued the use of amiodarone 
and of the remaining 53 patients, 11 developed AITD, 9 
were diagnosed as AIH and 2 as AIT. The incidence rate of 
AITD was 62.8 per 1000 patients/year (95%CI: 31.3-112.3), 
Table 1. Demographic, clinical and laboratory baseline evaluation according to thyroid function status of patients taking amiodarone.
Euthyroid AIH AIT P
N (%) 62 (51.2%) 50 (41.3%) 9 (7.5%)
Age (years) 57.9 ± 13.7 57.6 ± 11.9 65.2 ± 16.9
Gender (female/ male, % female) 27/35 (39.7%) 34/16 (50%) 7/2 (77.7%) 0.014a
Time of amiodarone intake prior to enrollment (months)
Mean ± SD 46.0 ± 49.3 49.2 ± 47.3 40.5 ± 51
Median (range) 31 (6-300) 28 (7-161) 15 (8-164)
Dose, N (%)
≤250 mg 42 (67.7%) 35 (70%) 8 (88.9%)
>250 mg 20 (32.3%) 15 (30%) 1 (11.1%)
Cardiac rhythm disorder, N (%)
SVT 29 (46.7%) 18 (36%) 4 (44.4%)
VT 26 (41.9%) 30 (60%) 4 (44.4%)
IND 7 (11.2%) 2 (4%) 1 (11.1%)
Baseline cardiac condition, N (%) 0.032a
CAD 11 (17.7%) 6 (12%) 1 (11.1%)
Cardiomyopathy 42 (67.7%) 27(54%) 4 (44.4%)
Valvular disease 7 (11.3%) 12 (24%) 1 (11.1%)
Other 2 (3.2%) 5 (10%) 3 (33.3%)
Overt clinical disease, N (%) 0 16 (32%) 7 (77.7%)
Laboratory evaluation of thyroid function (mean ± SD)
TSH (mU/L) 1.5 ± 0.92 20.61 ± 28.19 0.06 ± 0.04 <0.001b
FT3 (pg/mL) 2 ± 0.55 2.48 ± 0.67 2.75 ± 1.08 0.003b
FT4 (ng/mL) 1.45 ± 0.36 0.98 ± 0.44 2.06 ± 0.31 0.001b
Anti-TPO (U/L) 22 ± 14.01 528.21 ± 1267.26 29.22 ± 14.47 0.045b
Reference values: thyrotrophin (TSH) = 0.3-4.0 mU/L; free triiodothyroxine (FT3) = 1.5-4.1 pg/mL; free thyroxine (FT4) = 0.7-1.7 ng/
mL; antithyroid peroxidase antibody (anti-TPO) = >35 U/L. AIH = amiodarone-induced hypothyroidism; AIT = amiodarone-induced 
thyrotoxicosis; SVT = supraventricular tachycardia; VT = ventricular tachycardia; IND = indeterminate; CAD = coronary artery disease. 
Data were analyzed statistically by the chi-square test (a) for categorical variables and by the Kruskal-Wallis test (b) for continuous 
variables, as appropriate.
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the rate for AIH was 51.3 per 1000 patients/year (95%CI: 
23.4-97.5), and the rate for AIT was 11.4 (95%CI: 1.38-
41.2). Figure 1 provides the Kaplan-Meier curve for AITD. 
Adjusting for age, gender, dose, and duration of treatment 
did not change our results. When we limited the follow-
up time to 6 months in our sensitivity analysis, the AITD 
incidence rate was 39.3 per 1000 patients/year (95%CI: 
9.2-61.9), not very different from the 1 year follow-up 41.7 
per 1000 patients/year (95%CI: 5.2-150.8).
Discussion
The prevalence of AITD varies according to iodine intake 
supplementation, presence of subclinical thyroid disorders 
and AITD definition (1,4,7). Our results show a high preva-
lence of AIH (41.3%), and a low prevalence of AIT (7.5%) 
probably because our region is an area of sufficient iodine 
intake. For areas such as ours with iodine sufficiency, a 
prevalence of 25% for AIH and a 2% prevalence of AIT 
Figure 1. Kaplan-Meier survival curve for the 62 patients with-
out thyroid dysfunction at baseline who developed amiodarone-
induced thyroid dysfunction (AIDT) over a mean period of 3.2 
years of follow-up.
Table 2. Demographic, clinical and laboratory baseline evaluation of patients for amiodarone-induced hypothyroidism according to 
clinical manifestation status.
Subclinical Clinical P
N (%) 34 (68%) 16 (32%)
Age (years) 57.0 ± 10.5 58.8 ± 14.8
Gender (female/male, % female) 24/10 (70.6%) 10/6 (62.5%)
Time of amiodarone intake prior to enrollment (months) 
Mean ± SD 52.0 ± 45.5 42.8 ± 52.4
Median (range) 33.5 (7-156) 16 (9-161)
Dose, N (%)
≤250 mg 24 (70.6%) 11 (68.7%)
>250 mg 10 (29.4%) 5 (31.3%)
Cardiac rhythm disorder, N (%)
SVT 12 (35.3%) 6 (37.5%)
VT 20 (58.8%) 10 (62.5%)
IND 2 (5.9%) 0 (0%)
Cardiac baseline condition, N (%)
CAD 4 (11.7%) 2 (12.5%)
Cardiomyopathy 17 (50.0%) 10 (62.5%)
Valvular disease 10 (29.4%) 2 (12.5%)
Other 3 (8.8%) 2 (12.5%)
Laboratory evaluation of thyroid function (mean ± SD)
TSH (mU/L) 7.57 ± 4.13 48.3 ± 36.8 <0.001a
FT3 (pg/mL) 2.5 ± 0.7 2.4 ± 0.5
FT4 (ng/mL) 1.1 ± 0.3 0.4 ± 0.1
Anti-TPO (U/L) 729.2 ± 1577.6 203.5 ± 288.5 <0.001a
Reference values: thyrotrophin (TSH) = 0.3-4.0 mU/L; free triiodothyroxine (FT3) = 1.5-4.1 pg/mL; free thyroxine (FT4) = 0.7-1.7 ng/
mL; antithyroid peroxidase antibody (anti-TPO) = >35 U/L. SVT = supraventricular tachycardia; VT = ventricular tachycardia; IND = 
indeterminate; CAD = coronary artery disease. Data were analyzed statistically by the Kruskal-Wallis test (a) for continuous variables 
and by the chi-square test for categorical variables.
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induced by amiodarone has been reported (11), lower 
values than those observed in the present study. These 
findings may reflect differences between populations, such 
as a higher prevalence of females in our group. They may 
also reflect the fact that there was no standard protocol 
in our institution for routine thyroid function screening for 
patients taking amiodarone prior to 2001. In addition, the 
prevalence in our study was much higher than that for the 
general population, which ranges from 7 to 10%, using TSH 
levels for clinical diagnosis. 
One of the confounding factors for studying AITD preva-
lence is the lack of data considering baseline thyroid func-
tion for persons who start amiodarone. Specifically among 
patients with hypothyroidism, subclinical autoimmune 
disorders could be responsible for hypothyroidism during 
follow-up or may be precipitated by amiodarone intake. It 
was impossible to evaluate this among our patients with 
hypothyroidism at baseline, even though the higher anti-TPO 
levels in this group could have suggested this possibility. 
TPO antibodies are the hallmark of AITD and reflect the 
severity of the lymphocytic infiltration, regardless of the pres-
ence or absence of hypothyroidism. The presence of TPO 
antibodies increases the risk of developing hypothyroidism 
during treatment with amiodarone (11).
Our results agree with reports that could not find a 
relationship between AITD and dosage or duration of 
amiodarone treatment (4,7,8,12,13). We also could not 
demonstrate that a baseline cardiac condition such as 
Chagas’ disease was associated with AITD. Silva et al. (14) 
detected AITD among 83 Chagas’ disease patients and 
found prevalence rates of 28% for AIH and of 10% for AIT, 
while considering only our 53 Chagas’ disease patients, the 
prevalence rates for AIH were 33.9% (18 cases) and 5.6% 
for AIT (3 cases). Even though our findings were similar 
considering AIH, we detected at least half the prevalence 
of AIT, which could reflect differences in population char-
acteristics. Of note, there was a higher incidence of goiter 
among the Chagas’ disease patients studied by Silva et al. 
(14), while there were no cases of goiter in our group. 
The prevalence of clinically overt thyroid disease was 
strikingly low (32%) among AIH patients, while the opposite 
was found for the AIT group (77.7%), observations that are 
again consistent with previous reports (1,4,8,13). It should 
be emphasized that thyroid dysfunction was evaluated by 
a trained endocrinologist according to formal standards 
(9,15). Since AIH is the most prevalent amiodarone-induced 
thyroid dysfunction, these findings support the recommen-
dation for screening.
The 53 baseline euthyroid patients from the same area 
without a history of thyroid dysfunction, using a chronically 
stable dose of amiodarone for more than 6 months, repre-
sent a highly selected group, but a very common clinical 
scenario. The high incidence of AITD should be attributed 
to the primary effect of the drug on the thyroid instead 
of an exacerbation of a chronic subclinical disease or a 
misdiagnosis, which is very common in the early phase 
of treatment with this drug because of the fluctuations of 
thyroid hormone levels. Even in this selected population, the 
incidence of AITD was very high, again further supporting 
the need for screening.
Recommendations for screening vary depending on 
the report or guideline, probably reflecting some of the 
problems previously described, with intervals ranging from 
3 months to more than 1 year (1,4,7). If we consider the 
more clinical scenario represented by our population, it 
seems reasonable to recommend an interval of 6 months if 
there are no clinical signs or symptoms of thyroid dysfunc-
tion. To recommend a shorter screening interval, we would 
have to have better information regarding the prognosis of 
untreated subclinical AITD, which, in the light of available 
evidence, seems to be very favorable (1), especially for the 
more prevalent type of AIH.
Our study has some limitations. First, some censoring 
bias may have been left in our data since we included for 
analysis only the patients who were being followed at our 
cardiology outpatient clinic. These could, in theory, represent 
only the patients who had not suffered any complication with 
amiodarone prior to inclusion. Another limitation that should 
be kept in mind concerns other factors that could impact 
on AITD, such as iodine intake. If this is not kept constant 
during follow-up, there may be different incidence rates and 
new screening strategies might be appropriate.
AITD is common even after excluding potential con-
founders that could be responsible for the high prevalence 
rates that have been described, which further support the 
current recommendations for screening. It seems reason-
able to recommend screening for thyroid function at 6-month 
intervals, unless clinical follow-up dictates otherwise or 
further information regarding the prognosis of untreated 
subclinical AITD is available.
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